Bristol-Myers Squibb Company (BMS) is an American multinational biopharmaceutical company headquartered in Princeton, New Jersey. Formed by the 1989 merger of Bristol-Myers and Squibb, it focuses on the discovery, development, manufacturing, and marketing of innovative medicines for serious diseases.
The company operates in key therapeutic areas including oncology, hematology, immunology, cardiovascular, and neuroscience. Leading products include Eliquis (apixaban) for atrial fibrillation, Opdivo (nivolumab) for cancer immunotherapy, Revlimid (lenalidomide) for multiple myeloma, Orencia (abatacept) for autoimmune conditions, and Reblozyl (luspatercept) for anemia. BMS is publicly traded on the NYSE under the ticker BMY and maintains a global presence with facilities worldwide.
Also known as Bristol Myers Squibb and Bristol-Myers Squibb.
chemXplore tracks 1 project involving BMS.
BMS's role on them: Owner and Operator.
FDA updates PAH therapy label to include HYPERION data showing a 76% reduction in clinical worsening when added to background therapy for patients diagnosed within 12 months.
Phase Ib/II trial will test DLL3/CD3 T‑cell engager plus PD‑L1/VEGF‑A bispecific in extensive‑stage SCLC to boost durable antitumor immunity; dosing to start H2 2026
Met primary endpoint with significant PVR reduction at 24 weeks vs placebo. Also favorable mPAP/PAWP, NT‑proBNP and 6MWD trends, delayed clinical worsening; safety consistent with known profile.
